CompanyGraph
Makes insulin and weight-loss injection drugs inside FDA-approved factories in Indianapolis that took a century to build.
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is higher than 95% of all stocks globally
- FinancialsAltman Z-Score: safe zone
- Interpretations6 currently firing — 1 · 5
What this company is and how it runs — written from structure, not news.
Eli Lilly makes insulin and GLP-1 therapies by growing engineered proteins inside bioreactors at its Indianapolis facility, purifying each batch over a 14-to-21-day cycle, and filling the result into prefilled injection devices. Because FDA approval attaches to that specific site, its specific cell lines, and its specific process steps — not to the molecule itself — the century of deviation records, yield histories, and inspection correspondence that Indianapolis has accumulated is what allows Lilly to modify an analog and reach approval faster than any competitor starting that archive from zero today. Adding more bioreactor hardware elsewhere could replicate the physical process, but the multi-year FDA inspection cycle and comparability studies required to validate a new site cannot be shortened by spending more money, so meaningful new capacity takes years to bring online. The same concentration that makes Indianapolis irreplaceable is also the single point through which all regulatory risk flows — a contamination event or consent decree there would suspend the validated process entirely, and no alternative site could absorb insulin volume quickly enough for Type 1 diabetic patients who face a medical crisis without it.
How does this company make money?
The company sells prefilled insulin pens and GLP-1 injection devices to pharmaceutical wholesalers, who then distribute them to pharmacies and hospitals. The price it actually receives is lower than the list price because it negotiates rebates with pharmacy benefit managers and accepts regulated pricing from government payer programs like Medicare. Revenue comes in per unit sold, so volume and the size of those rebates both determine how much money actually lands.
What makes this company hard to replace?
Patients who depend on insulin cannot simply swap to a different brand without a doctor supervising the transition and carefully adjusting the dose, because different insulin analogs do not behave identically in the body. Pharmacy benefit managers sign annual contracts that lock in pricing and preferred brand status, making mid-year switches commercially disruptive. Hospital IV insulin protocols name specific formulations, and changing those requires a formal approval process through a clinical committee.
What limits this company?
The bioreactor tanks in Indianapolis can only run so many batches at once, and each batch takes between 14 and 21 days no matter how much money is spent. Pouring in extra capital to speed things up would count as a process change, which then triggers a fresh round of regulatory review that itself takes months. The ceiling is physical and regulatory at the same time.
What does this company depend on?
The company cannot run without recombinant DNA plasmids that encode its insulin and GLP-1 drugs, FDA approval for its Indianapolis biologics facilities, specialized cell culture media containing amino acids and growth factors, prefilled pen injection devices from contract manufacturers, and European Medicines Agency manufacturing authorizations to supply patients in the EU.
Who depends on this company?
Type 1 diabetic patients depend on its insulin directly — without a continuous supply, they face ketoacidosis, which is life-threatening. Obesity treatment programs inside healthcare systems would lose access to the GLP-1 drugs Mounjaro and Zepbound if supply stopped. Pharmacy benefit managers, who build their diabetes drug lists around pricing agreements with this company, would also have to restructure those arrangements.
How does this company scale?
The recipes for making and purifying these proteins can be applied to additional bioreactor capacity with predictable results — that part scales in a straightforward way. What does not scale easily is regulatory approval of any new manufacturing site, which requires multi-year FDA inspection cycles and clinical comparability studies that cannot be shortened by spending more money.
What external forces can significantly affect this company?
Medicare now caps insulin prices at $35 per month for government-insured patients, which limits how much revenue the company can earn from that large group. In Europe, health technology assessment bodies require cost-effectiveness evidence before agreeing to reimburse diabetes drugs. Supply chain disruptions affecting pharmaceutical ingredients and device components sourced from China could interrupt production of both the drugs and the injection devices.
Where is this company structurally vulnerable?
If the FDA issued a consent decree or found confirmed contamination at the Indianapolis manufacturing site, it would suspend the validated process that all approvals depend on. No other facility is licensed and proven to absorb that volume. Type 1 diabetic patients, who face a life-threatening condition called ketoacidosis if their insulin supply stops, would have nowhere else to turn within any medically safe timeframe. The same concentration that makes the company hard to compete with is exactly what makes a single enforcement action so dangerous.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Multi-Year Up-Close-Week Share With Profitability And Book-Value Growth
Three observations describe the present configuration: a high share of the trailing three years' weekly closes were higher than the prior week, the company has reported positive net income in each of the last five annual periods, and the book-value-increase-consistency composite over the trailing 5 years is elevated.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
5 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Elevated EBITDA Margin With Small D&A Gap and Capex Above Depreciation
Three observations describe the configuration: EBITDA margin is elevated, EBIT is close to EBITDA (small D&A gap), and capex significantly exceeds depreciation. This pattern is consistent with a young or growing asset base, an asset-light industry profile, or a depreciation policy that understates economic wear.
Cash Backing With Revenue And Income Streaks
Three observations co-occur: the weighted composite of net cash relative to market cap, OCF/revenue, operating margin, and ROE is in its elevated range; revenue increased every year for three years; net income was positive every year for three years. The configuration describes a present-state combination of capital structure, cash generation, profitability, and top-line growth.
Operating Income Growing With Multi-Year Revenue Growth
Three observations describe the present configuration: operating income increased year-over-year in each of the last four fiscal years, the 6-year revenue CAGR is positive, and revenue increased year-over-year in each of the last five fiscal years. None of the three observations divides by revenue.
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
Revenue Growth With Elevated Margin
Three observations align on a healthy multi-year growth profile: revenue grew every year over the trailing five-year window, operating margin in the most recent year is at an elevated level, and revenue grew every year over the trailing three-year window. Together they describe sustained top-line continuity at a high current margin level.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.